[Reactogenicity and immunological effectiveness of a concentrated, purified vaccine against tick-borne encephalitis].
Human reactogenicity and immunological efficacy of concentrated purified tick-borne encephalitis (CTBEV) vaccine was studied in a controlled trial. The new vaccine was found to be superior to the commercial preparation in its capacity to induce specific humoral and cell-mediated immunity in man and in reduced sensitizing activity with regard to nonviral cellular antigens. Two vaccinations with CTBEV in doses of 0.5 ml each at 6-month interval are recommended. At this vaccination schedule virus neutralizing antibodies were detectable in 95% vaccines. Inoculation of 0.5 ml CTBEV is accompanied by fever of mild and moderate intensity in 19% and 3% of the vaccines, respectively. In this respect CTBEV is less reactogenic than the commercial preparation.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D004306:Dose-Response Relationship, Immunologic; D004341:Drug Evaluation; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D006801:Humans; D007114:Immunization; D008213:Lymphocyte Activation; D008297:Male; D013997:Time Factors; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification; D014765:Viral Vaccines / Q000009:adverse effects* / Q000276:immunology / Q000302:isolation & purification
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines
Reaktogennost' i immunologicheskaia éffektivnost' kontsentrirovannoĭ, ochishchennoĭ vaktsiny protiv kleshchevogo éntsefalita.